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Genetic and regulatory mechanism of susceptibility
to high-hyperdiploid acute lymphoblastic
leukaemia at 10p21.2
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Despite high-hyperdiploid acute lymphoblastic leukaemia (HD-ALL) being the most common
subgroup of paediatric ALL, its aetiology remains unknown. Genome-wide association studies
have demonstrated association at 10q21.2. Here, we sought to determine how this region
inﬂuences HD-ALL risk. We impute genotypes across the locus, ﬁnding the single nucleotide
polymorphism rs7090445 highly associated with HD-ALL (P¼ 1.54 10 38), and residing in
a predicted enhancer element. We show this region physically interacts with the transcription
start site of ARID5B, that alleles of rs7090445 have differential enhancer activity and
inﬂuence RUNX3 binding. RUNX3 knock-down reduces ARID5B expression and rs7090445
enhancer activity. Individuals carrying the rs7090445-C risk allele also have reduced ARID5B
expression. Finally, the rs7090445-C risk allele is preferentially retained in HD-ALL blasts
consistent with inherited genetic variation contributing to arrest of normal lymphocyte
development, facilitating leukaemic clonal expansion. These data provide evidence for a
biological mechanism underlying hereditary risk of HD-ALL at 10q21.2.
DOI: 10.1038/ncomms14616 OPEN
1 Division of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London SM2 5NG, UK. 2 Department of Laboratory
Medicine, Division of Clinical Genetics, Lund University, BMC C13, Lund SE-221 84, Sweden. 3 Division of Molecular Pathology, The Institute of
Cancer Research, 15 Cotswold Road, Sutton, London SM2 5NG, UK. Correspondence and requests for materials should be addressed to R.S.H.
(email: Richard.houlston@icr.ac.uk).
NATURE COMMUNICATIONS | 8:14616 | DOI: 10.1038/ncomms14616 | www.nature.com/naturecommunications 1
A
cute lymphoblastic leukaemia (ALL) is the most common
childhood malignancy. Twenty to twenty-ﬁve per cent of
ALL is characterized by high-hyperdiploidy (51–67
chromosomes), making high-hyperdiploid ALL (HD-ALL) one
of the major subgroups of paediatric cancer1. A characteristic
genetic feature of HD-ALL is the non-random gain of
chromosomes X, 4, 6, 10, 14, 17, 18 and 21, with individual
trisomies or tetrasomies seen in over 75% of cases2. High-
hyperdiploidy is almost exclusively observed in the context of
paediatric precursor B-cell ALL, with a peak incidence at 4 years
of age2, and has a more favourable outcome than other forms of
B-cell ALL (ref. 3). The aetiology of HD-ALL remains unknown,
however several lines of evidence are consistent with the initiating
transforming event occurring in utero4–6, suggesting additional
secondary events are required to trigger clonal expansion and the
development of overt disease.
Subsequent clonal expansion is likely to be inﬂuenced by both
inherited genetic susceptibility, and as yet unidentiﬁed environ-
mental risk factors. A number of genetic disorders are associated
with an increased risk of ALL including Down’s syndrome7 and
ataxia telangiectasia8. However, even collectively these account
for only a small proportion of ALL (ref. 9) and analyses of risk in
siblings of cases suggest that common genetic variation
contributes to disease susceptibility10.
Recently, independent genome-wide association studies
(GWAS) demonstrated robust association at a locus in the gene
AT rich interactive domain 5B (ARID5B) at 10q21.2 (refs 11,12).
Variation at this locus is primarily associated with HD-ALL
(refs 11,12), having no impact on the risk of ETV6/RUNX1
translocation positive ALL. Currently it is unclear how 10q21.2
inﬂuences the risk of developing HD-ALL. Elucidating the
function of this risk locus is therefore an important step
towards the development of testable hypotheses regarding the
biological processes involved in the pathogenesis of HD-ALL.
Here, we sought to identify the causal polymorphism(s) driving
the 10p21.2 genetic association with ALL susceptibility as a basis
for understanding HD-ALL initiation and addiction mechanisms.
We identify a potential mechanism contributing to the additional
risk to ALL conferred by 10p21.2. Variation at rs7090445 disrupts
RUNX3 binding and via a looping interaction reduces the
expression of ARID5B. Consistent with rs7090445 contributing to
ALL leukaemic blasts with the C-risk allele have reduced ARID5B
expression and preferentially duplicate the copy of chromosome
10 harbouring this variant.
Results
Fine mapping and epigenomic proﬁling of the 10p21.2 locus.
We ﬁrst ﬁne mapped the 10p21.2 risk locus by imputation using
UK10K and 1000 Genomes Project as reference and data from
two GWAS data sets totalling 465 HD-ALL cases, both previously
reported13. Supplementary Table 7 details whether SNPs in
the 10q21 risk loci were directly genotyped or imputed. This
identiﬁed eight SNPs with minor allele frequency (MAF) 40.01,
an association Po1.0 10 35 (ﬁxed-effects meta-analysis of
logistic regression P value) and an odds ratio of42.4 at 10p21.2
in HD-ALL (Fig. 1, Supplementary Table 8). All eight SNPs
localize to intron three of ARID5B and are in strong linkage
disequilibrium (LD) deﬁning a single risk haplotype (LD to the
lead SNP rs10821936 r2¼ 0.88–1.00; Supplementary Table 8 and
Supplementary Fig. 1). We further prioritized associated variants
by assessing their regulatory potential inferred through B-cell
speciﬁc DNase I hypersensitivity mapping and chromatin
immunoprecipitation sequencing (ChIP-seq) experiments in the
lymphoblastoid cell line (LCL) GM12878 and ALL blasts from
the ENCODE14 and Blueprint15 projects respectively (Fig. 2,
Supplementary Tables 9 and 10). These data highlighted SNPs
rs7896246 and rs7090445 (logistic regression P values 1.36
10 38 and 1.54 10 38, respectively) as plausible functional
SNPs based on their putative enhancer characteristics, deﬁned by
relevant histone markers (H3K27ac, H3K4me1 and H3K4me3),
transcription factor binding, DNase I hypersensitivity and
sequence conservation (Fig. 2; Supplementary Fig. 1).
rs7090445, rs7896246 and ARID5B expression. We next
examined if the genotypes of rs7090445 or rs7896246 were
associated with ARID5B expression. Gene expression was quan-
tiﬁed from RNA-sequencing data in 45 HD-ALL cases, of which
the majority, 30 (65%), were trisomic for chromosome 10, con-
sistent with previous ﬁndings2. To control for gene dosage we
restricted our expression quantitative trait locus (eQTL) analysis
to these trisomic blasts. Genotypes of both rs7090445 and
rs7896246 were associated with ARID5B expression, with the
rs7090445-C and rs7896246-A risk alleles associated with reduced
expression (ANOVA P¼ 0.029 and P¼ 0.020, respectively,
Fig. 3a,b). The risk alleles of rs7090445 and rs7896246 were
also associated with reduced ARID5B expression in disomic cases,
albeit non-signiﬁcantly (Supplementary Fig. 2). Following this we
tested for an eQTL with RTKN2 and C10orf107 which map within
a 500 kb window of rs7090445 and rs7896246. No eQTL was
detected for RTKN2 (P40.05) (Supplementary Fig. 3), and
C10orf107 was not expressed.
rs7090445 genotype inﬂuences enhancer activity. To measure
the effect of rs7090445 and rs7896246 alleles on enhancer activity
we performed luciferase reporter assays in MHH-CALL2 and
SEM BCP ALL cell lines. Transfection with constructs containing
the rs7090445 risk C-risk allele displayed signiﬁcantly lower
normalized luminescence compared to non-risk T-allele con-
structs (Two-tail t-test P¼ 0.008 and P¼ 0.028, Fig. 3c,d,
respectively). rs7896246 genotype did not impact on enhancer
activity (Supplementary Fig. 4a,b). These data are thus consistent
with a model of HD-ALL risk in which variation at rs7090445 is
associated with decreased expression of ARID5B.
rs7090445 modulates RUNX3 binding afﬁnity. We next inter-
rogated GM12878 Encode ChIP-seq data to identify differential
transcription factor (TF) binding for alleles of rs7896246 and
rs7090445. Reads mapping to each SNP allele from experiments
were mapped and enumerated (Supplementary Table 9). Only
RUNX3 at rs7090445 displayed a signiﬁcant read bias, with a
1.7-fold excess of reads mapping to the non-risk T allele
(Weighted Fisher’s combined binomial Po0.001, Fig. 4a). To
exclude the possibility this observation was a consequence of copy
number or other local cis variation we analysed whole genome
sequencing data from the same cell line ﬁnding no evidence of
allelic read bias (Binomial P¼ 1.0) or any other genetic variation
250 bps upstream or downstream of rs7090445, sequencing cov-
erage within this interval was at least 45X. To verify that RUNX3
also binds to rs7090445 in MHH-CALL2 we performed ChIP-
qPCR; enrichment for rs7090445 was observed relative to IgG
isotype controls, consistent with differential RUNX3 binding
driving allele speciﬁc enhancer activity (Supplementary Fig. 5).
We examined the possibility that variation at rs7090445 disrupts
overlapping motifs using in silico data from HaploReg v4.1
(ref. 16) in conjunction with ENCODE data. While motifs for
CUX1, HOXD8 and MEF2A were possibly disrupted by variation
at rs7090445 the surrounding loci contains mismatches at high
stringency bases for each TF and ENCODE data provided no
evidence for CUX1 or MEF2A binding (Supplementary Table 9;
Supplementary Fig. 6). To further examine the inﬂuence of
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rs7090445 genotype on function we performed an EMSA in
GM12878. Nuclear protein bound to the non-risk T allele of
rs7090445 with greater afﬁnity than the risk C allele. The addition
of an anti-RUNX3 antibody resulted in a supershift suggesting
RUNX3 is a component of this complex (Fig. 4b). Hence while
rs7090445 does not overlap with a predicted RUNX3 binding
motif, this is a common feature of ChIP-seq data, and suggests
RUNX3 may bind cooperatively with as yet unidentiﬁed addi-
tional factors17–19.
rs7090445 risk region interacts with the ARID5B promoter.
Various lines of evidence indicate that chromatin looping inter-
actions formed between enhancer elements and gene promoters
map within distinct chromosomal topological associating
domains (TADs). To examine the TAD structure of the 10q21
rs7090445 region and identify local chromatin patterns, we ana-
lysed publicly accessible Hi-C GM12878 data20 as a source of
B-cell information (Supplementary Fig. 7a). These data
demonstrated the transcription start site (TSS) of ARID5B
and the rs7090445 risk region map within a single TAD
(Supplementary Fig. 7a). Furthermore, accepting the caveat of
5 kb resolution of the Hi-C data, within this TAD the most highly
enriched contact of the rs7090445 risk region is with the TSS of
ARID5B, which showed a 2.7-fold enrichment over expected
levels (Supplementary Fig. 7b), consistent with a looping
interaction between these regulatory elements. Following from
this observation we performed 3C-qPCR in REH and MHH-
CALL2 ALL cell lines, GM12878 and HeLa cells to determine
chromatin looping interaction between the genomic region
encompassing rs7090445 and the ARID5B promoter. From 3C-
qPCR we demonstrated that rs7090445 forms chromatin looping
interaction with the TSS of ARID5B in cells of B-cell lineage but
not in HeLa cells (Fig. 5). Collectively these data suggest
a mechanism by which RUNX3-bound rs7090445 regulates
ARID5B expression in a tissue-speciﬁc manner. The genotype
of rs7090445 did not affect the contract frequency between these
two loci (Supplementary Table 11).
RUNX3 regulates ARID5B expression. To support a role for
RUNX3 in ARID5B regulation we analysed tumour gene expres-
sion data from three cohorts of paediatric B-ALL totalling 385
cases (GSE13425, GSE13351 (ref. 21) and LUND (ref. 22) data
sets). In each series ARID5B and RUNX3 expression were
positively correlated (Fig. 6; Weighted Fisher’s combined Spear-
man’s P¼ 5.6 10 5). While a consistent association was shown
between ARID5B and RUNX3 gene expression in HD-ALL the
small size of these subsets of the data may have precluded
demonstration of a statistically signiﬁcant relationship. No con-
sistent correlation between ARID5B and RUNX3 was observed in
ETV6/RUNX1 positive ALL (Supplementary Fig. 8). To establish
a direct relationship between RUNX3 and ARID5B expression we
conducted small interfering RNA (siRNA) experiments. Since
transfection efﬁciency was found to be poor in MHH-CALL2
cells, siRNA RUNX3 knockdown was performed in GM11832
(homozygous for rs7090445 T). We also conﬁrmed that RUNX3
binds to rs7090445 in GM11832 by ChIP-qRT (Supplementary
Fig. 5). Knockdown of RUNX3 was accompanied by a signiﬁcant
reduction in ARID5B messenger RNA (mRNA) (Two-tailed t-test
P¼ 2.4 10 3, P¼ 7.0 10 4, P¼ 1.2 10 3; RUNX3 siRNAs
1, 2 and 3, respectively: Fig. 7b). If RUNX3 contributes to the
allele speciﬁcity of the rs7090445 reporter assay its depletion
should be reﬂected in reduced luciferase activity. Cells depleted
for RUNX3, by siRNA, were subsequently transfected with the
high activity rs7090445 T-allele pGL3 vector construct. RUNX3
knockdown was also accompanied by reduced luciferase activity
(Fig. 7c).
rs7090445 risk allele is ampliﬁed in hyperdiploid B-ALL. Since,
trisomy of chromosome 10 is frequently observed in HD-ALL we
sought to determine whether the rs7090445 risk allele, associated
with reduced ARID5B expression, is preferentially ampliﬁed. To
investigate the relationship between heritable risk and somatic
mutation in HD-ALL we examined ALL blasts with both chro-
mosome 10 trisomy and heterozygous for rs7090445 (n¼ 31).
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Figure 1 | Genetic mapping and overall epigenetic landscape of the 10q21 HD-ALL risk locus. The region of association maps to an 8 kb haplotype block
within intron 3 of ARID5B. SNPs (dots) are shown based on their chromosomal position (GRCh37/hg19 human genome build) on the x axis and  log10
association P-value in HD-ALL on the y axis. Colour intensity of each SNP reﬂects the extent of linkage disequilibrium (white r2¼0 to dark red r2¼ 1) with
the lead SNP, rs10821936 (shown in black). Recombination rates, estimated using 1,000 genomes and UK10K samples of European ancestry, are shown by
a light blue line. Gene positions and chromatin state segmentation (ChromHMM) in GM12878 from ENCODE project data are shown. Also annotated are
the candidate functional SNPs rs7090445 and rs7896246, red dotted lines.
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Of these 21 had duplicated the risk allele (C) and 10 had dupli-
cated the non-risk allele (T) (Binomial test P¼ 0.035, Fig. 8).
Discussion
Collectively, our data demonstrate a plausible mechanism
underlying the 10q21 risk locus for HD-ALL being mediated
through rs7090445, which disrupts RUNX3 transcription factor
binding. Our data are compatible with the rs7090445-C allele
conferring increased HD-ALL risk through reduced RUNX3-
mediated expression of ARID5B. CRISPR/Cas9 genome editing of
rs7090445 should provide further support for these assertions,
given the limitations of luciferase-based assays. Furthermore,
epigenetic and chromosome conformation capture data are
consistent with rs7090445 localizing within a chromatin contact
domain and overlapping a B-cell enhancer. This interval,
anchored by CTCF binding sites, forms a ‘loop domain’ which
is expected to bring two regions of RUNX3 binding, separated by
a linear distance of around 60Kb, into physical contact close to
the TSS of ARID5B.
Here we have provided direct evidence that ARID5B is
transcriptionally regulated by RUNX3. ARID5B plays an impor-
tant role in embryogenesis and growth regulation. ARID5B forms
a complex with PHF2 (ref. 23), which has H3K9me2 histone
demethylase activity. H3K9me2 is one of the predominant
markers of repressed chromatin and as such ARID5B is
believed to play a role in epigenetic activation of gene
expression. Mouse models with targeted disruption of ARID5B
have reduced bone marrow cellularity and B220þ /IgM B-cell
progenitor cells populations24. Interestingly ALL blasts lack B220
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Figure 3 | rs7090445 is associated with lower ARID5B expression and reduced enhancer activity. Expression quantitative trait loci (eQTL) analysis
performed in HD-ALL trisomic for chromosome 10 for (a) rs7090445 and (b) rs7896246. Difference in RNA sequencing of ARID5B expression (RSEM)
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containing the 818bp putative regulatory sequence ﬂanking rs7090445 were cloned into the pGL3-promoter luciferase reporter vector and transfected into
(c) REH and (d) SEM cell lines. The ratio of luminescence from the experimental pGL3-rs7090445 constructs to the Renilla internal control, pRL-SV40,
normalized to the empty pGL3-SV40 promoter vector. Data shown are mean±s.e.m. from six independent experiments performed in triplicate. Difference
in gene expression assessed by Student’s T-test. Luciferase data were normally distributed. The rs7090445-C risk allele has signiﬁcantly decreased
enhancer activity over the protective allele.
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expression25. RUNX3, a Runt-related transcription factor has also
been implicated in the lineage speciﬁcation of lymphoid cells
where RUNX3 knock-out are associated with aberrant
differentiation of innate lymphocytes26.
It has been shown that chromosomal gains in HD-ALL often
arise prenatally4–6. No recurrent fusion gene-forming
rearrangements have however been observed in tumours, and
analysis of mutations on trisomic chromosomes indicates that
chromosomal gains are early events in tumorigenesis,
strengthening the notion that the acquisition of high-
hyperdiploidy is the main driver event in this common
paediatric malignancy27. Moreover sequencing data indicates a
latency period after the high-hyperdiploid pattern is established
in most patients. Hence the consequence of the chromosomal
gains is probably mediated through dosage effects, where
additional genetic aberrations are likely to be required for the
development of overt leukaemia. We have shown that individuals
carrying the rs7090445-C risk allele have reduced ARID5B
transcript levels, however chromosome 10, containing ARID5B,
is trisomic in around 70% of HD-ALL. We also show that HD-
ALL heterozygotes preferentially duplicate the chromosome 10
homologue carrying the rs7090445-C risk allele, potentially
allowing increased dosage of chromosome 10 genes relative to
ARID5B. The effects of chromosome 10 gain are likely driven by a
selective advantage conferred by increased dosage of additional
unknown factors unrelated to ARID5B. It is therefore possible
that preferential gain of the chromosome 10 homologue carrying
the risk allele is due to the conﬂicting selective forces acting to
reduce ARID5B expression, while simultaneously inducing dosage
effects associated with trisomy 10.
In conclusion we have shown that in individuals carrying
the rs7090445-C risk allele, ARID5B transcript levels are
reduced and this provides a mechanistic basis for the 10q21 risk
association for HD-ALL. This observation and the ﬁnding
that the risk allele of rs7090445 is preferentially retained on
additional copies of chromosome 10 in HD-ALL blasts are
compatible with the hypothesis that inherited genetic variation
contributes to decreased ARID5B expression and arrest of
normal lymphocyte development facilitating leukaemic clonal
expansion.
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Methods
Ethics. Collection of GWAS samples and clinicopathological information from
subjects was undertaken with informed consent in accordance with the Declaration
of Helsinki and with approval of the ethical review board. HD-ALL blast RNA
sequencing and genotyping sample collection was approved by the Ethical
Review Board at Lund University, no 2011/289. Consent was obtained from all
subjects.
Genome-wide association study. The United Kingdom (UK)-GWAS and Ger-
man-GWAS of B-cell precursor (BCP) ALL have been previously reported11,28.
Brieﬂy, the UK GWAS comprised 824 BCP-ALL cases, including 289 with HD-
ALL (mean age of diagnosis 5.5 years), genotyped using Illumina Human 317K
arrays (Illumina, San Diego). Controls were provided by the Wellcome Trust Case
Control Consortium 2 (http://www.wtccc.org.uk/) of 2,699 individuals in the 1958
British Birth Cohort genotyped using Hap1.2M-Duo Custom array data and 2,501
individuals from the UK Blood Service. The German GWAS comprised 1,155 cases,
including 176 with HD-ALL (mean age at diagnosis 6.0 years), genotyped using
Illumina Human OmniExpress-12v1.0 arrays. Controls comprised 2,024 healthy
individuals from the Heinz Nixdorf Recall study29 genotyped using Illumina
HumanOmni1-Quadv1 and HumanOmniExpress-12v1.0 arrays. GWAS quality
control (QC) has been described previously28. To recover untyped genotypes we
performed imputation using IMPUTE2 v2.3 (ref. 30) with a combined UK10K
(ref. 31) and 1000 Genomes Project (phase III)32 panel for reference. Poorly
imputed SNPs (INFO score o0.80) were excluded. Frequentist association testing
between SNP genotype and HD-ALL was performed using logistic regression under
an additive genetic model in SNPTESTv2.5 (ref. 33). Meta-analysis was undertaken
under a ﬁxed-effects model using inverse variance weighting in META v1 (ref. 33).
ENCODE and Blueprint chromatin state dynamics. Epigenetic proﬁles of asso-
ciation signals are composed of chromatin state segmentation (ChromHMM),
DNAse I hypersensitivity, transcription factor ChIP-Seq and histone modiﬁcation
data in the lymphoblastoid cell line GM12878 from the ENCODE project14 and
in leukaemic blasts from two paediatric precursor B-cell acute lymphoblastic
leukaemia cases from the Blueprint project15. The individual data sets used are
listed in Supplementary Table 10.
Cell lines. MHH-CALL2, SEM, REH B-ALL and HeLa cell lines were obtained
from the DMSZ (Braunschweig, Germany), GM12878 and GM11832 lympho-
blastoid cell lines (LCL) were obtained through the Coriell Institute (Camden NJ,
US). Cell lines were maintained at 37 C, with 5% CO2 in either RPMI with 10%
FBS (REH, GM12878 and GM11832), 20% FBS RMPI (MHH-CALL2) or 10%
DMEM (HeLa) supplemented with GlutaMAX (ThermoFisher Scientiﬁc, Wal-
tham, MA, USA). REH BCP-ALL cell line used as a model of ETV6:RUNX1
translocation positive ALL. Cell line identity conﬁrmed by translocation speciﬁc
PCR primers available on request. HeLa cell line used as a non B-cell control. Cell
lines were tested for mycoplasma (PCR Mycoplasma Test Kit I/C, PromoCell,
Heidelberg, Germany), no positive results were obtained.
Plasmid construction and luciferase assays. The putative regulatory regions
containing rs7090445 and rs7896246 were ampliﬁed from genomic DNA from the
CEU LCL cell lines NA12004 and NA10851 respectively using primers detailed in
Supplementary Table 1. Gel puriﬁed PCR-products (Qiagen, Hilden, Germany)
were A-tailed using 2U Thermprime DNA polymerase (ThermoFisher Scientiﬁc)
and 200 mM dATP for 30min at 70 C, and cloned into pCR/8/GW/TOPO
(ThermoFisher Scientiﬁc). Bacterial colonies were picked, cultured and puriﬁed
using Qiagen Mini-prep Kit. SNP risk alleles were generated using site-directed
mutagenesis (Quick Change XL, Agilent). Risk and non-risk variants were trans-
ferred into a Gateway compatible pGL3 Promoter vector using Gateway LR
Clonase II (ThermoFisher Scientiﬁc) and pGL3 constructs puriﬁed using Qiagen
Midi-prep kits. Inserts and single base changes were veriﬁed by Sanger sequencing.
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Figure 7 | RUNX3 drives ARID5B expression and enhancer activity of
rs7090445. mRNA expression quantitation of siRNA knockdown in the
lymphoblastoid cell line GM11832. Cells were transfected with one of three
RUNX3 siRNAs for 48 h, after which cells were assayed for expression of
RUNX3 (a) ARID5B (b) and re-transfected with the high activity T allele of
the rs7090445 pGL3 Promoter reporter construct (c). Gene expression
data in a,b normalized to the geometric mean of PPIA, TBP, G6PD
and LAMIN A/C. Data shown are mean ±s.e.m. from n¼4 (a,b),
n¼ 3 (c). Asterisk show the P value of a two sided Students t-test
(*Po0.05, **Po0.01, ***Po0.001). qRT-PCR expression data were
normally distributed.
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Figure 8 | The rs7090445 risk allele is preferentially retained in
high-hyperdiploid ALL. The genotype of rs7090445 was interrogated
in a series of high-hyperdiploid cases, 31 of which were trisomic for
chromosome 10 and heterozygous for rs7090445. P value calculated using
a one-sided binomial test.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14616 ARTICLE
NATURE COMMUNICATIONS | 8:14616 | DOI: 10.1038/ncomms14616 | www.nature.com/naturecommunications 7
Site-directed mutagenesis and sequencing primers are detailed in Supplementary
Tables 2 and 3. Cells were transiently transfected by electroporation using a
Nucleofector 2B (Lonza, Basel, Switzerland). 4 106 MHH-CALL2, 3 106
GM11832 and 2 106 SEM cells were transfected with 2.5 mg of pGL3 promoter
construct and 50 ng of pRL-SV40 (Promega, Madison, WI, United States ), for
normalization in 100ml of Solution V using either program X-01 (MHH-CALL2
and GM11832) or T-02 (SEM). After 16 h promoter activity was assayed using the
Dual-Luciferase reporter assay system (Promega) using a Fluoroskan Ascent FL
(Labsystems). Six biological replicates each containing 3 technical replicates, were
performed for MHH-CALL2 and SEM.
ChIP-seq. Proteins binding rs7896246 and rs7090445 were inferred from Encode
ChIP-Seq data (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/
wgEncodeRegTfbsClustered/ wgEncodeRegTfbsClusteredV3). ChIP-seq fastq data
for proteins binding to either loci was downloaded from Encode (http://hgdown-
load.cse.ucsc.edu/goldenPath/hg19/encodeDCC/) and whole genome fastq data for
the GM12878 was downloaded from Illumina Platinum Genomes project
(AC:ERR194147). Fastq data were aligned to the human reference genome
(human_g1k_v37), edited to mask common SNPs in build 141, using Stampy
v1.0.28 sequence alignment tool. Allele speciﬁcity of ChIP-seq data was assessed
using a binomial test of allele speciﬁc read counts, assuming an equal distribution.
Biological replicates were analysed separately and combined using Fisher’s method.
Electromobility shift assay. Nuclear protein was extracted from GM12878 cells
using NE-PER nuclear and cytoplasmic extraction kits (Thermo Fisher Scientiﬁc).
Fluorescently labelled (DayLight 682 nM) and unlabelled complementary oligo-
nucleotides (Euroﬁns Genomics) ﬂanking rs7090445 (50-AACAGCCTAACCTAG
GTTAT[T/C]GATAGCTTTGAGACCTTCTG-30) were annealed to generate
double-stranded EMSA probes. Each 20 ml binding reaction contained 50 fmol
labelled target DNA, 1 binding buffer (10mM Tris, 30mM KCl, 2mM DTT,
2.5% glycerol, 0.01mgml 1 BSA [pH 7.5], 1 mg polydI-dC [Sigma-Aldrich] and
10mg nuclear protein extract). Reactions were incubated in the dark for 30min at
room temperature. Competition assays were performed by adding 200-fold molar
excess of unlabelled probes. Super-shifts were performed by adding 2 mg RUNX3
antibody (Santa Cruz Biotechnology, sc-376591) to the binding reaction and
incubating for 15min before the addition of labelled probe. DNA-protein
complexes were resolved by electrophoresis on a 6% DNA retardation gel
(Life Technologies) in 0.5 Tris-borate-EDTA (TBE) at 4 C. Gels were imaged
using the Odyssey Fc Infrared Imaging System (LI-COR Biosciences).
An uncropped EMSA gel image is provided in Supplementary Fig. 9.
ChIP q-RT PCR. ChIP was performed using the Active Motif ChIP-IT Express kit
(Active Motif, La Hulpe Belgium), with the modiﬁcation that after mircococcal
nuclease digestion of DNA, cells were sonicated in a Biorupter for 10min at 4 C,
to aid chromatin release. 25mg of chromatin was incubated with 1 mg of anti-
RUNX3 (Santa Cruz sc-376591) or 1 mg IgG2b (ThermoFisher Scientic, MA5-
14447). After washing qRT-PCR was performed using primer sequences detailed in
Supplementary Table 6. Three biological replicates were performed using separate
chromatin preparations. Interpolated quantities for each target were normalized to
an input DNA sample, without antibody pull-down.
Hi-C data analysis. Hi-C data derived from GM12878, digested with MboI, was
retrieved from the NCBI (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE63525)20. Data from replicates were combined and analysed using
a balanced Knight-Ruiz normalization method34, and viewed at 5 kb resolution.
Chromatin conﬁrmation capture. Chromatin conﬁrmation capture (3C) libraries
were generated according to Naumova et al.35 A control 3C template was generated
using minimally overlapping BAC clones RPCI20I18 (RP11-20I18) and
RPCI508P23 (RP11-508P23) (Source Bioscience, Cambridge UK). Taqman
reactions were performed in triplicate with four biological replicates using 150 ng of
DNA ampliﬁed using thermoprime DNA polymerase (ThermoFisher Scientiﬁc)
and analysed using an ABI7900HT (Applied Biosystems). Raw data signals were
normalized to ligated BAC clones and an internal loading control. Primer, probe
sequences and cycling conditions are detailed in Supplementary Table 5.
PCR-products were veriﬁed by Sanger sequencing.
qRT-PCR. qRT-PCR was performed using SYBR Green PCR master mix
(ThermoFisher Scientiﬁc). Samples were analysed undiluted for ChIP assays or
1/100 diluted in H20 for siRNA assays. Each biological replicate contained three
technical replicates. PCR quantitation was by standard curve method. Five-fold
serial dilutions of DNA or complementary DNA (cDNA) were used to control for
differential primer efﬁciency. For siRNA assays target gene expression was nor-
malized to the geometric average of PPIA, TBP, G6PD and LAMIN A/C.
siRNA transfection and reverse transcription. GM11832 homozygous for
rs7090445 T-allele was transiently transfected by electroporation using 200 nM of
siRNA (Euroﬁns Genomics, Ebersberg, Germany) for 48 h (siRNA sequences
detailed in Supplementary Table 4) and then either re-transfected using the T-allele
construct of pGL3 and pRL-SV40, or lysed. RNA was prepared using the Qiagen
RNAeasy kit. 1–2mg of RNA was reverse transcribed using MMLV (Promega) and
5 uM dT (ref. 14) per guidelines. Pooled cDNAs diluted 1/20 in H20 were used for
standard curve quantitation.
Gene expression in BCP-ALL. mRNA expression data on paediatric B-cell ALL
was retrieved from Gene Expression Omnibus accessions GSE13425 (n¼ 154) and
GSE13351 (n¼ 92) and RMA-normalized using a custom array deﬁnition ﬁle from
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/20.0.0/
ensg.asp) using the R packages Affy and limma. RNA-seq data from 139 B-cell ALL
was quantiﬁed using RSEM as described previously22. Spearman correlation
coefﬁcient and associated P values were calculated in R version 3.2.2.
SNP array and RNA sequencing. 90 cases of HD-ALL were genotyped using
either Illumina Human 1M-duo Inﬁnium BeadChip, HumanOmni1-Quad Bead-
Chip or IlluminaOmni5M BeadChips27,36. 45 of the 90 ALL blasts were also RNA
sequenced on a HiScanSQ (Illumina, San Diego CA, US) as previously described22.
Gene Expression levels were estimated by using TCGA UNC V2 RNA-seq
workﬂow and normalized RNA-Seq by Expectation Maximization (RSEM) values
were then log2(xþ 1) transformed. To control for ploidy effects only cases with
chromosome 10 trisomy for were considered for genotype expression correlations
and chromosome duplication bias tests.
Data availability. Existing GWAS data is available from the authors upon
request13. Existing RNA sequencing in ALL blasts is available from the authors on
request22. Existing genotyping data in HD-ALL blasts is available from the authors
upon request27. Publically available data used in this study can be found as
deposited in the following data sets; DNAse I hypersensitivity data from GM12878:
NCBI Gene Expression Omnibus GSE32970, DNAse I hypersensitivity data ALL
blasts: European Genome-phenome Archive EGAD00001002499, H3K27ac/
H3K4me1/H3K4me3 and H2AZ ChIP sequencing data from GM12878:
NCBI Gene Expression Omnibus GSE29611, H3K27ac/H3K4me1/H3K4me3
sequencing data ALL blasts: European Genome-phenome Archive
EGAS00001000326, RUNX3 ChIP-seq data from GM12878: NCBI Gene
Expression Omnibus GSE32465, GM12878 whole genome sequencing: Illumina
Platinum Genomes project AC:ERR194147, ChromHMM in GM12878: NCBI
Gene Expression Omnibus GSE38163. Microarray expression data in ALL blasts:
NCBI Gene Expression Omnibus GSE13425 and GSE13351. The remaining data
within the Article and Supplementary Information ﬁles are available from the
authors upon request.
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